These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37204251)

  • 21. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
    Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
    Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
    D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
    Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
    BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.
    Ali A; Bhatti MZ; Shah AS; Duong HQ; Alkreathy HM; Mohammad SF; Khan RA; Ahmad A
    J Biol Chem; 2015 Aug; 290(35):21336-51. PubMed ID: 25911104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.
    Dhar G; Banerjee S; Dhar K; Tawfik O; Mayo MS; Vanveldhuizen PJ; Banerjee SK
    Cancer Res; 2008 Jun; 68(12):4580-7. PubMed ID: 18559502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling.
    Xu M; Zhang X; Zhang S; Piao J; Yang Y; Wang X; Lin Z
    Aging (Albany NY); 2020 Dec; 13(1):1032-1050. PubMed ID: 33293473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
    Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
    Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
    Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
    Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis.
    Zhang Y; Liu JL; Wang J
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3085-3096. PubMed ID: 32271426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASF1B enhances migration and invasion of lung cancers cell via regulating the P53-mediated epithelial-mesenchymal transformation (EMT) signaling pathway.
    Wang W; Xiao L; Pan D; Hu L
    Neoplasma; 2022 Mar; 69(2):361-369. PubMed ID: 35103478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
    Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
    Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.
    Ruan JW; Liao YC; Lua I; Li MH; Hsu CY; Chen JH
    Breast Cancer Res; 2012 Jul; 14(4):R106. PubMed ID: 22789011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells.
    Adhikary A; Chakraborty S; Mazumdar M; Ghosh S; Mukherjee S; Manna A; Mohanty S; Nakka KK; Joshi S; De A; Chattopadhyay S; Sa G; Das T
    J Biol Chem; 2014 Sep; 289(37):25431-44. PubMed ID: 25086032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-κB signaling pathway.
    Zhang M; Qiu S
    Anticancer Drugs; 2019 Mar; 30(3):260-270. PubMed ID: 30520776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
    Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
    Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.